pixel
THREEFOLD IMPROVEMENT IN OVERALL SURVIVAL

TIBSOVO + azacitidine delivered a median overall survival of 24.0 months (95% CI, 11.3‑34.1)
vs 7.9 months (95% CI, 4.1‑11.3) with azacitidine (hazard ratio, 0.44; P<0.0010)1

AML Home Chart
SIGNIFICANTLY HIGHER RATES OF CR AND CR+CRh

47% of patients achieved CR on TIBSOVO + azacitidine
(95% CI, 35-59; P<0.0001) vs 15% on azacitidine (95% CI, 8-25)1

51% of patients achieved CR or CRh on TIBSOVO + azacitidine
(95% CI, 39-63; P<0.001) vs 18% on azacitidine (95% CI, 10-28)1

SAFETY
TIBSOVO has a well-characterized safety profile studied in more than 270 patients with mIDH1 AML1

BOXED WARNING: Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. TIBSOVO is associated with the following Warnings and Precautions: differentiation syndrome, QTc prolongation, and Guillain-Barré syndrome.1

discover-icon
A RECOMMENDED TREATMENT OPTION

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend ivosidenib (TIBSOVO) + azacitidine as a category 1 preferred treatment option for newly diagnosed patients ≥60 years of age with mIDH1 who are not candidates for intensive remission induction therapy.3

Discover the importance of IDH1 testing at diagnosis and relapse

FIRST-IN-CLASS DIFFERENTIATION THERAPY1,4
Single-agent TIBSOVO helps achieve multiple treatment goals for your patients with difficult‑to‑treat mIDH1 AML1

In newly diagnosed, IC‑ineligible AML

In
R/R AML

bottle with two pills
STRAIGHTFORWARD DOSING REGIMEN
TIBSOVO offers a straightforward dosing regimen with no titration needed1

RESOURCES

about TIBSOVO for you
and your practice

Discover | Home

SUPPORT

with ServierONE Patient Support Services for access and financial assistance

Servier One | Home

Choose TIBSOVO + azacitidine to maximize overall survival for your newly diagnosed, IC-ineligible mIDH1 patients1

AZA, azacitidine; CI, confidence interval; CR, complete remission, defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, full recovery of peripheral blood counts (absolute neutrophil count ≥1000/μL and platelets ≥100,000/μL), and independence of red blood cell transfusions2; CRh, complete remission with partial hematological recovery, defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, and partial recovery of peripheral blood counts (absolute neutrophil count >500/μL and platelets >50,000/μL)2; HR, hazard ratio; mIDH1, mutated isocitrate dehydrogenase-1; NCCN, National Comprehensive Cancer Network® (NCCN®); OS, overall survival; R/R, relapsed or refractory.

References: 1. Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2022. 2. Data on file. Servier Pharmaceuticals LLC. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed July 21, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300-305. doi:10.1021/acsmedchemlett.7b00421
 
pixel pixel
 

INDICATIONS

TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with:

Newly Diagnosed Acute Myeloid Leukemia (AML)

  • In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy
  • Adult patients with relapsed or refractory AML.
Indications & Important Safety Information

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME IN AML

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.